Google
SNN 株価分析 — SMITH & NEPHEW SNATS INC (Healthcare >> Medical Devices)
SNN に関するよくある質問
SNNのPER（株価収益率）は？
SMITH & NEPHEW SNATS INC（SNN）は現在PER 13.26倍で取引されています。
SNNのROE（自己資本利益率）は？
SMITH & NEPHEW SNATS INCのROEは11.84%です。
SNNの配当利回りは？
SMITH & NEPHEW SNATS INCの配当利回りは2.39%です。
SNNの品質スコア（Quality Score）は？
当社のAIはSNNの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SNNは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SNNはどのセクターに属しますか？
SMITH & NEPHEW SNATS INCはHealthcare >> Medical Devicesセクターに分類されます（NYSE市場）
SNN AI Analysis Summary
Our AI summary for SNN: SMITH & NEPHEW SNATS INC (NYSE), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 13.26, ROE of 11.84%, a dividend yield of 2.39%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 31.56
Price
-0.77
(-2.38%)
Day Change
|
|
|---|
SNN, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 74 |
| Magic Formula Rank by ROA |
1218
|
| Magic Formula Rank by ROE |
1218
|
| Magic Formula Rank by ROIC |
1079
|
| Price | 31.56 |
| PBV / Sector |
2.60 / -101.57
|
| Earning Per Share | 1.44 |
| PE / Sector |
13.26 / 31.23
|
| PEG or PE/Growth / Sector |
0.23 / 0.40
GREAT
|
| Average 1M Daily Value |
51.35 M
|
| Average 1W Daily Value |
63.36 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:30 |
| Symbol | SNN |
| Name | SMITH & NEPHEW SNATS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE |
| Listed Shares | 420.26 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 13,774.90 / 20,104.97 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 5, Watford, United Kingdom, WD18 8YE
Phone: 44 1923 477 100
Website: https://www.smith-nephew.com
Employees: 16,988
Sector: Healthcare >> Medical Devices
Description: Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
